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Abstract
Mice with disruption of Lrrk1 and patients with nonfunctional mutant Lrrk1 exhibit
severe osteopetrosis phenotypes because of osteoclast cytoskeletal dysfunction. To
understand how Lrrk1 regulates osteoclast function by modulating cytoskeleton
rearrangement, we examined the proteins that are differentially phosphorylated in
wild‐type mice and Lrrk1‐deficient osteoclasts by metal affinity purification coupled
liquid chromatography/mass spectrometry (LC/MS) analyses . One of the candidates
that we identified by LC/MS is L‐plastin, an actin bundling protein. We found that
phosphorylation of L‐plastin at serine (Ser) residues 5 was present in wild‐type
osteoclasts but not in Lrrk1‐deficient cells. Western blot analyses with antibodies
specific for Ser5 phosphorylated L‐plastin confirmed the reduced L‐plastin Ser5
phosphorylation in Lrrk1 knockout (KO) osteoclasts. micro computed tomography
(Micro‐CT) analyses revealed that the trabecular bone volume of the distal femur
was increased by 27% in the 16 to 21‐week‐old L‐plastin KO females as compared
with the wild‐type control mice. The ratio of bone volume to tissue volume and
connectivity density were increased by 44% and 47% (both P<0.05), respectively, in
L‐plastin KO mice. Our data suggest that targeted disruption of L‐plastin increases
trabecular bone volume, and phosphorylation of Ser5 in L‐plastin in the Lrrk1
signaling pathway may in part contribute to actin assembly in mature osteoclasts.
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1 | INTRODUCTION
Osteoporosis is one of the most physically debilitating
conditions associated with aging. There are two major
known causes of osteoporosis: low peak bone mineral
density, which typically appears around the age of 30, and
a high bone loss rate that occurs particularly after
menopause and during the natural aging process. Bone loss
occurs with age in part because the rate of bone resorption
(BR) surpasses the rate of bone formation (BF). Effective
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inhibitors of BR, such as bisphosphonates, have been widely
used in the clinic to treat high turnover bone diseases.
However, treatment with bisphosphonates results in sup-
pression of BF besides BR and blunts the anabolic actions of
parathyroid hormone (PTH).1 Because bisphosphonates are
incorporated within the bone matrix with high affinity, long
term treatment with these drugs may impair fracture healing,
cause jaw osteonecrosis, and increase the risk for atypical
fractures of the femur.2-6 Although cathepsin K inhibitor has
shown promise in large animal and human clinical studies,
treatment with cathepsin K inhibitor causes periosteal BF
due to decreased growth hormone degradation.7 Disconti-
nuation of cathepsin K inhibitor results in reversal of
treatment effects.8 Therefore, novel antiresorptives that avoid
antianabolic actions are needed to enhance endosteal BF and
improve fracture repair.
In our previous studies, we have demonstrated that
mice with disruption of the Lrrk1 gene displayed a severe
osteopetrosis phenotype resulting from the dysfunction of
mature osteoclasts (OC). OCs lacking LRRK1 failed to
form peripheral sealing zones and ruffled borders on
bone slices due to defects in receptor activator of nuclear
factor- κB ligand (RANKL)‐induced cytoskeletal rearran-
gement.9 In contrast to bisphosphonate‐treated mono-
cytes, precursors derived from Lrrk1 knockout (KO) mice
differentiate normally into mature OCs but fail to resorb
bone. While BR in KO mice is reduced dramatically, BF is
not significantly affected. Lrrk1 KO mice have normal
teeth, are healthy through 1 year of age, and respond to
anabolic PTH treatment, but are resistant to ovariectomy‐
induced bone loss.9 More recently, mutations in the Lrrk1
gene have been identified in human patients.10 The
clinical features of affected patients resulting from the
dysfunction of Lrrk1 in OC were very similar to the
skeletal phenotypes observed in the Lrrk1 KO mice.9,10
These studies suggest that Lrrk1 could be an antagonist
drug target for treatment of osteoporosis.
Lrrk1 contains a protein kinase C (PKC)‐like serine/
threonine protein kinase domain and a guanosine tripho-
sphate (GTP) binding Roc domain to which GTP binding
stimulates Lrrk1 kinase activity in vitro. Our structure‐
function studies revealed that ANK, ROC, and the kinase
domains of Lrrk1 were essential for the Lrrk1 mediated BR
function in OCs.11 We have also demonstrated that Tyr‐527
phosphorylation of c‐Src was altered in Lrrk1 deficient
OCs.9 Phosphorylation and activation of Rac1/Cdc42 were
also reduced in Lrrk1 KO cells.11 Because mice with Lrrk1
disruption exhibit a more severe osteopetrosis phenotype
than c‐Src KO mice and Rac1/Rac2 double KO mice, it can
be predicted that Lrrk1 signaling may target other signaling
molecules besides the c‐Src/Rac1/Cdc42 small GTPase
signaling pathways via posttranslational modification.12 To
understand how Lrrk1 regulates formation of F‐actin rings
and podosomes in OCs, we have examined proteins that are
differentially phosphorylated in the wild type (WT) and
Lrrk1 deficient OCs by LC/MS. In this study, we show that
L‐plastin is differentially phosphorylated in Lrrk1 deficient
OCs and that disruption of the L‐plastin gene in mice
causes an osteopetrosis phenotype.
2 | MATERIALS AND METHODS
2.1 | Recombinant proteins and
antibodies
Recombinant macrophage colony-stimulating factor (M‐
CSF) and RANKL were ordered from R&D Systems
(#3588; Minneapolis, MN). A pan antibody specific to
L‐plastin was obtained from the Cell Signaling Technology
(Danvers, MA) and an antibody specific to phospho‐L‐plastin
at residue serine 5 was obtained from Signalway Antibody
(#12455; Baltimore, MD). A polyclonal antibody against
β‐actin was purchased from Sigma (#122M4782; St. Louis,
MO). A High‐SelectTM TiO2 Phosphopeptide Enrichment Kit
was obtained from Thermo Fisher Scientific (#A32993;
Waltham, MA).
2.2 | In vitro osteoclast culture and
differentiation
Primary OC precursors were isolated from the spleen of
5‐week‐old Lrrk1 KO and WT mice as described
previously.9 The isolated precursors were maintained in
α‐MEM supplemented with 10% fetal bovine serum,
penicillin (100 U/mL), streptomycin (100 µg/mL), and
M‐CSF (20 ng/mL) at 37°C in 5% CO2 for 3 days to
stimulate monocyte proliferation. The cells were then
induced to differentiate in a medium containing 20 ng/ml
M‐CSF and 30 ng/mL RANKL for 5‐6 days. Differentiated
OCs were retreated with fresh 20 ng/mL M‐CSF and
30 ng/mL RANKL for 30minutes before harvesting and
lysing for Western blot or mass spectrometry analyses.
2.3 | Mass spectrometry (MS) and
Western blot analyses
Mature OCs derived from the spleen of Lrrk1 KO and WT
control mice were lysed in a denaturing lysis buffer
containing 4M guanidine hydrochloride, 50 mM Tris‐
HCl (pH 8.0), 150mM NaCl, 10 mM MgCl2, and 5mM
TCEP‐HCl for 20minutes at room temperature followed
by centrifugation at 12 000 rpm for 10minutes. The
cellular lysates were reduced, precipitated twice with
four volumes of acetone, and digested with trypsin
(0.1 mg/mL in 50mM NH4HCO3) at 37°C overnight.
Digested peptide lysates were desalted with a Sep‐Pac
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C18 cartridge and dried. The phospho‐peptides were
enriched with spherical porous titanium dioxide (TiO2)
resin spin tips from the High‐ SelectTM TiO2 Phospho‐
peptide Enrichment Kit according to the manufacturer’s
instructions. The enriched phospho‐peptides were then
dried, resuspended in 0.1% formic acid, and directly
subjected to LS/MS at the University of California,
Riverside, MS Core Facility. An aliquot of total cellular
lysate (30 μg) was separated by 10% NuPAGE for Western
blot analysis as described previously.11
2.4 | Micro CT analyses of
formalin‐fixed long bones
Dr. Sharon Celeste Morley from the Washington University
School of Medicine, St. Louis, MO, USA provided 10%
formalin fixed femurs from 16 to 21‐week‐old WT and L‐
plastin KO female mice.13 Bone micro‐architectures were
assessed by µ‐CT (Scanco Invivo CT40, Switzerland) as
described previously.14,15 The bone in PBS was scanned by X‐
ray at 55 kVp volts (trabecular bone) or at 75Kvp volts
(cortical bone) at a resolution of 10.5 µm/slice. A scout view
of the whole bone was used to measure the bone length and
to select the sampling sites. The region of the trabecular bone
was analyzed from the distal femur between 0.315 and
1.365mm (second spongiosa) above the distal femur growth
plate. For femoral cortical bone analysis, 0.525‐mm slices on
each side of the center (total 1.05mm, 100 slides) were
analyzed. Parameters such as bone volume (BV; mm^3), the
ratio of BV to tissue volume (BV/TV, %), trabecular number
(Tb.N, mm−1), trabecular thickness (Tb.Th., mm), trabecular
space (Tb.Sp., mm), and connectivity density (Conn.D., 1/
mm^3) were compared between L‐plastin KO females and
WT control mice. All procedures were performed with the
approval of the Institutional Animal Care and Use
Committee of VALLHCS and Washington University School
of Medicine, St. Louis, MO, USA.
2.5 | Statistical analysis
Data are presented as mean± SEM and analyzed by the
Student t test or two‐way analysis of variance as appropriate.
3 | RESULTS
3.1 | Phosphorylation of L‐plastin at
serine (Ser) residues 5 was reduced in
Lrrk1‐deficient cells
Lrrk1 consists of ankyrin repeats, leucine rich repeats, a
GTPase‐like domain of Roc, a COR domain, a PKC‐like
serine/threonine kinase domain, and WD40 repeats. It is
believed that kinase activity is required for Lrrk1 function in
OCs.11 To identify the proteins that are differentially
phosphorylated in the WT and Lrrk1 deficient OCs, total
cellular proteins were extracted from mature OCs derived
from WT and Lrrk1 KO mice, and the trypsin‐digested
peptides were then examined for the serine/threonine
residues phosphorylation by LS/MS analyses. One of the
identified protein was L‐plastin, which was phosphorylated
FIGURE 1 Phosphorylation of L‐plastin at serine (Ser) residues 5 was absent in Lrrk1 deficient cells. OC precursors derived from Lrrk1
knockout and control wild‐type mice were differentiated in the presence of RANKL and M‐CSF into mature OCs and lysed for protein
extraction. Cellular proteins were digested with trypsin and the phospho‐peptides were enriched with spherical porous titanium dioxide
(TiO2) resin spin tips for LS/MS analyses. Phosphorylation of L‐plastin, an actin bundling protein, at Ser5 was only present in WT mature
OCs but not in Lrrk1 deficient cells as detected by LC/MS. LC/MS, liquid chromatography/mass spectrometry; M‐CSF, macrophage colony-
stimulating factor; OC, osteoclasts; RANKL, receptor activator of nuclear factor- κB ligan; WT, wild type
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at Ser5 in WT but not Lrrk1 KO OCs (Figure 1). To confirm
this finding, Western blot analyses were carried out with an
antibody specific for phosphoserine, Ser5 phosphorylated L‐
plastin, and a pan antibody specific to total L‐plastin. Figure
2A shows Coomassie blue staining of WT and KO OC lysate
to show that similar amounts of total protein had been
loaded. Immunoblotting analyses with an antiphosphoserine
antibody revealed reduced phosphorylated protein with a
molecular weight of 65 kDa in Lrrk1 deficient OC lysates
(Figure 2B). A parallel blot with anti‐Ser5‐L‐plastin antibody
recognized the same 65 kDa phosphorylated protein in WT
cells, and reduced phosphorylated L‐plastin in Lrrk1 KOOCs
(Figure 2C). The expression level of either total L‐Plastin or
β‐actin was unaffected in Lrrk1 KO OCs, as expected.
3.2 | L‐plastin KO mice exhibit mild
osteopetrosis in long bones
To determine the role of L‐plastin in regulating bone mass,
we examined the micro‐architecture of long bones derived
from 16 to 21‐week‐old female mice by micro‐CT. There was
no significant difference in the length of the femurs fromWT
and KO mice (15.45± 0.08 vs 15.1 ± 0.16mm, P>0.05).
Micro‐CT analyses revealed that trabecular BV of the distal
femur was increased by 27% in the 16 to 21‐week‐old
L‐plastin KO females compared with the gender‐matched
WT control mice (P>0.05). However, the BV to tissue
volume ratio (BV/TV) and connectivity density were
significantly increased by 44% and 47%, respectively, in
L‐plastin KO mice (Figure 3 A‐C & Figure 3G). There were
no significant differences in the trabecular number, thick-
ness, or separation between KO and WT femurs
(Figures 3D‐F). Cortical bone phenotypes were not signifi-
cantly affected by the lack of L‐plastin. The BV, TV, and BV/
TV of the cortical bone samples were comparable between
the femurs derived fromWT and KOmice (data not shown).
4 | DISCUSSION
In our previous studies, we demonstrated that Lrrk1
deficient monocytes can differentiate into larger, TRAP‐
positive multinuclear OCs. However, these mature OCs
either showed diffused F‐actin in the cytoplasm and
failed to assemble sealing rings on bone slices, or form
giant flat cells on the bone surface that are not associated
with resorption pits.9 The dysfunction of Lrrk1 deficient
OCs contributed to the disruption of cytoskeletal
rearrangement, sealing ring formation, and podosome
assembly in OCs. However, the mechanisms by which
Lrrk1 influenced cytoskeletal organization remained
unknown. In the current study, we demonstrated, by
proteomic approaches, that phosphorylation of L‐plastin
at serine residues 5 was present in WT mature OCs, but
was absent in differentiated Lrrk1 deficient OCs, and that
deficiency of L‐plastin in female mice caused an increase
FIGURE 2 Reduced L‐plastin Ser5 phosphorylation in Lrrk1 KO OCs by Western Blot. OC precursors derived from WT and Lrrk1 KO
mice were differentiated in the presence of RANKL and M‐CSF, and total cellular protein was extracted for Western blot analyses with
specific antibodies. A, Coomassie blue staining of total protein from WT and KO OCs. B, Western blot detects differential levels of
serine‐phosphorylated proteins between WT and Lrrk1 KO cells. C, Western blot shows that Ser5 is phosphorylated but does not show the
that the level of L‐Plastin (LPL) was affected in LRRK1 KO OCs. The anti‐phospho‐L‐plastin antibody was obtained from Signalway
Antibody (#12455; Baltimore, MD). KO, knockout; OC, osteoclasts; WT, wild type
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in trabecular bone volume leading to mild osteopetrotic
phenotypes. Our micro‐CT scanning also found that lack
of L‐plastin in OCs did not change the cortical bone
volume or the femur length of the long bones.
In previous studies, it was found that L‐plastin
deficient OCs exhibited normal differentiation and
peripheral podosomes, but these cells showed significant
decreases in the formation of the adhesive contact with
the bone surface.16 It has also been demonstrated that
phosphorylation of L‐plastin at serine residue 5, after a
variety of stimuli, leads to increased stability of actin‐
based OC sealing rings, and podosomes that are critical
for osteoclast adhesion, and the early process of BR.16
Our findings together with other laboratories suggest that
phosphorylation of Ser5 of L‐plastin is involved in the
Lrrk1 signal pathways, and may in part contribute to the
disrupted cytoskeletal rearrangement in Lrrk1 deficient
OCs, and the reduced BR observed Lrrk1 KO mice.
L‐plastin is phosphorylated on serine 5 and serine 7 in
hematopoietic cells in vivo in response to signals triggering
the activation of the immune response, cell migration, and
proliferation.16-18 Although in vivo and in vitro phosphoryla-
tion of serine 5 by cyclic adenosine monophosphate (cAMP)‐
dependent protein kinase A is well documented, it is still
unknown which kinase(s) phosphorylate serine 7.17,18
Lommel et al19recently provided evidence that the extra-
cellular signal-regulated kinase/mitogen-activated protein
kinase (ERK/MAPK) pathway was involved in L‐plastin
serine 5 phosphorylation in breast cancers, with ribosomal S6
kinase 1 and 2 able to directly phosphorylate the L‐plastin
FIGURE 3 L‐Plastin KO mice exhibit mild osteopetrosis in long bones. Femurs isolated from 16 to 21‐week‐old WT and L‐plastin KO
female mice were scanned by micro‐CT images. A & B, Representative micro‐CT images show an increased bone volume in the distal
metaphysis of the femur in L‐plastin KO female as compared to WT control mouse. C‐H, Quantitative data of the trabecular bone parameters
of the distal femoral metaphysis in WT control (N = 6) and L‐Plastin KO (N= 8) mice show increases in the ratio of BV to tissue volume
(BV/TV) and connectivity density. P< 0.05 indicates statistical significance. BV, bone volume; KO, knockout; OC, osteoclasts; TV, tissue
volume; WT, wild type
SI ET AL. | 10355
serine 5 residue. Other potential candidate kinases that are
involved in L‐plastin phosphorylation are PKC and PI3K.20-22
Interestingly, the N‐terminal sequence of L‐plastin proteins
(RGSVS) does bear the consensus substrate motifs (R/KxS)
for PKC protein kinases.23 Because Lrrk1 is an MAPKKK
that contains a PKC‐like serine/threonine protein kinase
domain, it is possible that Lrrk1 directly phosphorylates the
serine residues of PKC substrate motifs. Although we
demonstrated in this study that serine 5 phosphorylation of
L‐plastin was present in WT OCs, we do not have evidence
that L‐plastin is a direct biological substance of Lrrk1.
Further studies are needed to determine if Lrrk1 directly or
indirectly modifies L‐plastin serine residues in OCs.
We found that the magnitude of increase in trabecular
bone mass was much smaller in L‐plastin KO as
compared with the severe osteopetrosis phenotype
observed in the Lrrk1 KO female mice of similar ages.9
We also noted that the integrin αvβ3, c‐Src, and Rac/
cdc42 small GTPase proteins are key regulators of the OC
cytoskeleton and activity.24-27 Deletion of any of these
signaling molecules compromises the capacity of OCs to
remodel the cytoskeleton and resorb bone, leading to
osteopetrosis phenotypes. Interestingly, mice with dis-
ruption of integrin, Src or RAC/Cdc42 proteins exhibited
a less severe bone phenotype than Lrrk1 KO mice,
suggesting Lrrk1 may phosphorylate multiple biological
substrates and be involved in multiple signaling path-
ways in OCs, and L‐plastin might be one of the Lrrk1
targets in the Lrrk1 signaling pathways.
The limitations of our study are as follows. First, the role
of L‐plastin downstream of Lrrk1 such as actin bundling,
F‐actin ring formation, and other potential L‐plastin target
membrane receptors (eg RANK and M‐CSF receptor) and/
or other membrane proteins in OCs was not studied
becuase it has been reported that L‐plastin phosphorylation
facilitates the surface transport of activation‐induced
receptors and immune synapse formation in T cells.28,29
Second, histomorphometric analyses were not performed to
confirm that reduced BR is the cause for increased
trabecular bone mass in the KO mice. Third, the skeletal
phenotype was evaluated only in L‐plastin KO females but
not males. Further studies are needed to confirm the
skeletal phenotype of L‐plastin KO in males and elucidate
the molecular mechanisms by which Lrrk1 regulates
L‐plastin phosphorylation.
In conclusion, we have demonstrated that targeted
disruption of L‐plastin increases trabecular bone
volume but had no effect on cortical bone. The
magnitude of increase in trabecular bone mass,
however, is much smaller in L‐plastin KO versus Lrrk1
KO mice of similar ages. Lrrk1 phosphorylation of Ser5
of L‐Plastin may in part contribute to actin assembly in
mature OCs.
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